アフリベルセプト ベータ（遺伝子組換え） 化学特性,用途語,生産方法
説明
In November 2011, the U.S. FDA approved the recombinant fusion
protein aflibercept, administered as an intravitreal injection, for the treatment
of patients with neovascular (wet) age-related macular degeneration
(AMD).
Aflibercept differs from these agents
in that it acts as a soluble decoy receptor that binds all VEGF isoforms
more tightly than their native receptors, thereby diverting VEGF from
its normal function. Aflibercept consists of a fusion of the second Ig
domain of human VEGF receptor 1 and the third Ig domain of human
VEGF receptor 2 fused to the constant region of (Fc) of human immunoglobulin
G1. Aflibercept is a dimeric glycoprotein with a protein molecular
weight of 97 kDa and glycoside molecular weight of 18 kDa. It is
produced in recombinant Chinese hamster ovary (CHO) cells that overexpress
the fusion protein. Aflibercept has subpicomolar affinity for
VEGF-A (K
D=0.66 pM for VEGF-A
165 and 0.19 pM for VEGF-A
121),
the major driver of pathological angiogenesis and vascular leak in wet
AMD.19 Ranibizumab and bevacizumab bind VEGF-A
165 with lower affinity
(K
D=20.6 and 35.1 pM, respectively).
Originator
Regeneron Pharmaceuticals (United States)
brand name
Eylea
アフリベルセプト ベータ（遺伝子組換え） 上流と下流の製品情報
原材料
準備製品